For a better experience of our website please update you web browser from IE11 to Microsoft Edge or an alternative modern browser such as Google Chrome. Thank you.

Escientia Life Sciences website logo


A big thank you to all our customers and new contacts at DCAT NY

In a world increasingly dominated by digital strategy and the use of Big data, algorithms, AI we can’t overemphasize how important it is to conduct some high-level meetings personally.

At Escientia we have significant plans to have a carbon-neutral site in Basel by 2028. Our other sites are being targeted with sustainability projects and in some cases investing to repurpose the type of chemistry we conduct. This somewhat complex and diverse strategy is part of our overarching strategy of Embracing Exceptional Life.

We should not forget that a lot of ongoing business is conducted at DCAT but our overall objective is to produce better value, more effective pharma which can benefit more people worldwide. We know that operating positives are needed to fund R&D and to invest in new technology. We, therefore, need to agree with customers not only on the work we are doing but also on the type of company we aim to become in the next five years.

This explanation of our plans to ethically embrace our responsibilities in Climate Change are equal to health and safety. In face to face conversations even behind a mask, you can take feedback and ideas on improvement which benefit customers and society.

Our meetings at DCAT have been commercially successful as well as giving us the ability to compare notes on creating more sustainable manufacturing solutions for a healthier planet.

Escientia Management

Joseph Colleluori joins the Escientia Board

Joseph Colleluori will Join Our Board of Directors

Global pharma CDMO Escientia is delighted to announce that Joseph Colleluori will join our board of directors.

Joe brings with him extensive experience in strategy and acquisition in the pharma world having spearheaded many successful projects at Merck & Co and Lonza as an executive in diverse senior roles for over 25 years.

Commenting on the announcement, Dr Yadagiri Pendri, CEO and Marcel Velterop, Co-CEO of Escientia, stated: “We are very privileged to be able to have Joe join our board and help us embrace exceptional life for patients, building powerful sustainable partnerships with pharma biotechs and large innovators.”

Joe Colleluori commented: “Exciting times to be joining the Escientia board as they prepare for rapid growth and entry into new areas of innovation helping fuel an exceptional life services provider. I am personally happy to join a great organization such as Escientia and look forward to working with management to hone and advance their ambitious growth plans.”

“Net Zero Carbon” by 2028 for our Swiss CDMO plant near Basel

Escientia declares its goal of reaching net zero by working closely with its partner Getec Park.Swiss by 2028.

In line with our new promise and purpose to ‘embrace exceptional life’, we are on the right path to source all our utilities and energy supply to make our production of RSM’s, GMP intermediates and API’s fully net zero.

In phase 2 we will strive to meet the global climate goals and reach net zero for the integrated supply chain latest by 2050.

Deccan invests in Escientia

The Deccan business brings with it a great heritage of sustainability, backward integration into fine-chemical building blocks and large-scale capacity across its multiple sites. A strategic review and upgrade of Escientia’s sustainability as a business is being conducted with a view to improving and enhancing our capability in the USA and Hyderabad.

Our 40-acre manufacturing site at Vizag is already considered one of the most modern in India. Further upgrades of the Basel facility acquired in the last year are being facilitated.

Click here to visit the Deccan website